Ramesh K Ramanathan

Ramesh K Ramanathan

UNVERIFIED PROFILE

Are you Ramesh K Ramanathan?   Register this Author

Register author
Ramesh K Ramanathan

Ramesh K Ramanathan

Publications by authors named "Ramesh K Ramanathan"

Are you Ramesh K Ramanathan?   Register this Author

100Publications

2870Reads

36Profile Views

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 11 4;36(33):3298-3306. Epub 2018 Oct 4.

John H. Strickler, Duke University Medical Center, Durham, NC; Colin D. Weekes, University of Colorado, Aurora, CO; John Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Ramesh K. Ramanathan, Virginia Piper Cancer Center at Honor Health/Translational Genomics Research Institute, Scottsdale, AZ; Rebecca S. Heist, Massachusetts General Hospital Cancer Center, Boston, MA; Daniel Morgensztern, Washington University School of Medicine, St. Louis, MO; Eric Angevin, Gustave Roussy, Villejuif, France; Todd M. Bauer, Sarah Cannon Research Institute; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Huibin Yue, Daniel Afar, and Louie Naumovski, AbbVie Inc.; Apurvasena Parikh, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Redwood City; Karen Kelly, University of California Davis Comprehensive Cancer Center, Sacramento, CA; and Monica Motwani, Edward B. Reilly, AbbVie Inc., North Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.7697
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.7697DOI Listing
November 2018

Novel immunotherapy strategies for hepatobiliary cancers.

Immunotherapy 2018 09;10(12):1077-1091

Department of Medicine, Division of Hematology & Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0024DOI Listing
September 2018

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 08 23;36(24):2545-2556. Epub 2018 May 23.

Davendra P.S. Sohal, Alok Khorana, and Smitha Krishnamurthi, Cleveland Clinic, Cleveland OH; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; Mehmet S. Copur, CHI Health St. Francis Cancer Treatment Center, Grand Island, NE; Christopher H. Crane, The University of Texas MD Anderson Cancer Center, Houston, TX; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Cassadie Moravek, Pancreatic Cancer Action Network, Manhattan Beach, CA; Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center; Joseph T. Ruggiero and Manish A. Shah, New York-Presbyterian/Weill Cornell Medical Center, New York, NY; Philip A. Philip, Barbara Ann Karmanos Cancer Institute, Farmington Hills; Susan Urba, University of Michigan Health System Comprehensive Cancer Center, Ann Arbor, MI; Ramesh K. Ramanathan, Mayo Clinic; Michelle W. Lau, Phoenix VA Medical Center, Phoenix, AZ; Hope E. Uronis, Duke University, Durham, NC; and Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9636DOI Listing
August 2018

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma.

Cancers (Basel) 2018 Jun 11;10(6). Epub 2018 Jun 11.

Department of Hematology/Medical Oncology, Mayo Clinic Cancer Center, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025083PMC
June 2018

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.

Future Oncol 2018 Mar 20;14(6):553-566. Epub 2018 Feb 20.

Division of Hematology Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0451DOI Listing
March 2018

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

J Clin Oncol 2018 01 28;36(3):276-282. Epub 2017 Nov 28.

Milind Javle and Rachna T. Shroff, The University of Texas MD Anderson Cancer Center, Houston, TX; Maeve Lowery and Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Karl Heinz Weiss and Christoph Springfeld, Universitäts Klinikum Heidelberg, Heidelberg, Germany; Mitesh J. Borad, Ramesh K. Ramanathan, and Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ; Lipika Goyal and Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Boston, MA; Saeed Sadeghi and Richard S. Finn, David Geffen School of Medicine at UCLA; Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles; Robin Kate Kelley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Teresa Macarulla, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Ivan Borbath, Cliniques Universitaires Saint-Luc, Brussels; Eric Van Cutsem, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium; Su Pin Choo, National Cancer Centre of Singapore, Singapore; Do-Youn Oh, Seoul National University, Seoul, South Korea; Philip A. Philip, Karmanos Cancer Institute, Detroit, MI; Li-Tzong Chen, National Institute of Cancer Research and National Cheng Kung University Hospital, Tainan; Kun-Huei Yeh, National Taiwan University Hospital Cancer Center, and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan; Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kristen Ciombor, The Ohio State University Wexner Medical Center, Columbus, OH; and Anuradha Patel, Suman Sen, Dale Porter, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075847PMC
January 2018

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

Cancer 2017 Dec 17;123(23):4680-4686. Epub 2017 Aug 17.

Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30927DOI Listing
December 2017

Targeting the stroma in pancreatic cancer.

Chin Clin Oncol 2017 Dec;6(6):65

Department of Hematology/Medical Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.11.02DOI Listing
December 2017

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

JCO Precis Oncol 2017 1;2017. Epub 2017 Aug 1.

David L. Marks, Tara L. Hogenson, Anne M. Vrabel, Ashley N. Sigafoos, Ezequiel J. Tolosa, Ryan M. Carr, Stephanie L. Safgren, Elisa Enriquez Hesles, Luciana L. Almada, Paola A. Romecin-Duran, Eriko Iguchi, Aryan Ala'Aldeen, Jean-Pierre A. Kocher, Gavin R. Oliver, Naresh Prodduturi, David W. Mead, Asif Hossain, Norine E. Huneke, Colleen M. Tagtow, Sikander Ailawadhi, Stephen M. Ansell, Michaela S. Banck, Asher A. Chanan-Khan, Ronald S. Go, Thorvardur R. Halfdanarson, Richard W. Joseph, Prashant Kapoor, Aaron S. Mansfield, Amulya A. Nageswara Rao, Grzegorz S. Nowakowski, Animesh Pardanani, Sameer A. Parikh, John C. Cheville, Andrew L. Feldman, Ramesh K. Ramanathan, Steven I. Robinson, Heidi D. Finnes, Jennifer B. McCormick, Robert R. McWilliams, Aminah Jatoi, Mrinal M. Patnaik, Eric D. Wieben, Tammy M. McAllister, Kandelaria M. Rumilla, Sarah E. Kerr, Konstantinos N. Lazaridis, Gianrico Farrugia, Karl J. Clark, Eric W. Klee, and Martin E. Fernandez-Zapico, Mayo Clinic, Rochester; Ernesto Resnik, Bio-Techne, Minneapolis, MN; Sikander Ailawadhi, Asher A. Chanan-Khan, and Richard W. Joseph, Mayo Clinic, Jacksonville, FL; Jan B. Egan, Alan H. Bryce, Estrella M. Carballido, KellyK. Curtis, Chelsea D. Gawryletz, Thai H. Ho,Nathalie Meurice, Ramesh K. Ramanathan, Raoul Tibes, Alvin C. Silva, A. Keith Stewart, and Mitesh J. Borad, Mayo Clinic, Phoenix, AZ; and Eileen J. Kennedy, University of Georgia, Athens, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924PMC
August 2017

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Pancreas 2017 02;46(2):203-208

From the *Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany; †Mayo Clinic, Scottsdale, AZ; ‡Prince of Wales Hospital, Sydney, New South Wales, Australia; §Celgene Corporation, Summit, NJ; and ∥Translational German Research Institute and Honor Health Research Institute, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000000742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266413PMC
February 2017

Immunotherapy in pancreatic cancer treatment: a new frontier.

Therap Adv Gastroenterol 2017 Jan 17;10(1):168-194. Epub 2016 Oct 17.

Division of Hematology/Oncology, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756283X16667909DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330603PMC
January 2017

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2016 08 31;34(23):2784-96. Epub 2016 May 31.

Davendra P.S. Sohal and Alok A. Khorana, Cleveland Clinic, Cleveland, OH; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Manish A. Shah, The Weill Cornell Medical Center; Philip A. Philip, Karmanos Cancer Institute, Detroit; Susan Urba, University of Michigan Cancer Center, Ann Arbor, MI; Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center; Joseph T. Ruggiero, Weill Cornell Medical College, New York, NY; Hope E. Uronis, Duke University, Durham, NC; Ramesh K. Ramanathan, Mayo Clinic, Scottsdale; Michelle Lau, Community Hospital Based Cancer Center, Tempe, AZ; Christopher H. Crane, The University of Texas MD Anderson Cancer Center, Houston, TX; Anitra Engebretson, Patient Representative, Portland, OR; Mehmet S. Copur, St Francis Medical Center, Grand Island, NE; and Daniel Laheru, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019760PMC
August 2016

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

J Gastrointest Oncol 2016 Jun;7(3):469-78

1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2016.01.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880765PMC
June 2016

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.

Nanomedicine 2015 Oct 17;11(7):1797-807. Epub 2015 Jun 17.

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2015.05.007DOI Listing
October 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Oncologist 2015 Feb 12;20(2):143-50. Epub 2015 Jan 12.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Division of Oncology, University of Washington, Seattle, Washington, USA; Department of Oncology/Hematology, Sarah Cannon Research Institute, Nashville, Tennessee, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Department of Oncology, Peninsula Oncology Centre, Monash University, Frankston, Victoria, Australia; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA; Division of Clinical Oncology, Medizinische Universität Wien, Vienna, Austria; Mayo Clinic, Scottsdale, Arizona, USA; Department of Oncology, Prince of Wales Hospital, Randwick, New South Wales, Sydney, Australia; Celgene Corporation, Summit, New Jersey, USA; Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319641PMC
February 2015

Disseminated intravascular coagulation secondary to advanced pancreatic cancer treated successfully with combination chemotherapy.

Oncology 2014 15;87(5):266-9. Epub 2014 Aug 15.

Virginia G. Piper Cancer Center, Scottsdale, Ariz., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000365552DOI Listing
January 2015

Unusual relapse of primary central nervous system lymphoma at site of lumbar puncture.

Case Rep Hematol 2014 29;2014:161952. Epub 2014 Jun 29.

Palo Verde Cancer Centre, 10460 N. 92nd Street, Suite 402, Scottsdale, AZ 85258, USA.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/crihem/2014/161952/
Publisher Site
http://dx.doi.org/10.1155/2014/161952DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100395PMC
August 2014

Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.

J Natl Cancer Inst 2014 Mar 22;106(3):dju011. Epub 2014 Feb 22.

Affiliations of authors: Taussig Cancer Institute and Lerner College of Medicine (DPSS, AAK) and Digestive Disease Institute and Lerner College of Medicine (RMW), Cleveland Clinic, Cleveland, OH; Virgina G. Piper Cancer Center, Translational Genomics Research Institute, Scottsdale, AZ (RKR).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/106/3/dju011.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/dju011
Publisher Site
http://dx.doi.org/10.1093/jnci/dju011DOI Listing
March 2014

Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

Nanomedicine 2014 Jan 24;10(1):109-17. Epub 2013 Jul 24.

Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, NC, USA; Translational Oncology and Nanoparticle Drug Development Initiative (TOND(2)I) Lab, UNC, Chapel Hill, NC, USA; Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA; UNC GLP Bioanalytical Facility, Chapel Hill, NC, USA; Institute for Pharmacogenomics and Individualized Therapy (IPIT), Chapel Hill, NC, USA; Carolina Center of Cancer Nanotechnology Excellence (C-CCNE), Chapel Hill, NC, USA; North Carolina Biomedical Innovation Network (NC BIN), Chapel Hill, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2013.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877184PMC
January 2014

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N Engl J Med 2013 Oct 16;369(18):1691-703. Epub 2013 Oct 16.

From the Translational Genomics Research Institute, Phoenix, and Virginia G. Piper Cancer Center, Scottsdale - both in Arizona (D.D.V.H., R.K.R.); Cancer Specialists, Fort Myers, FL (T.E.); Arena Oncology Associates, Lake Success (F.P.A.), and Roswell Park Cancer Institute, Buffalo (W.W.M.) - both in New York; University of Washington, Seattle (E.G.C.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (J. Infante); Princess Margaret Hospital, Toronto (M.M.); Atlanta Cancer Care (T.S.) and Georgia Cancer Specialists (M.N.S.) - both in Atlanta; Blokhin Cancer Research Center, Moscow (S.A.T.); Southern Health, East Bentleigh, VIC (M.H.), Prince of Wales Hospital, Sydney (D.G.), and Bionomics, Thebarton, SA (J. Iglesias) - all in Australia; San Raffaele Scientific Institute, Milan (M.R.); Tom Baker Cancer Centre, Calgary, AB, Canada (S.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (D.L.); University of Pittsburgh Medical Center, Pittsburgh (N.B.); Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona (J.T.); Centro Integral Oncológico Clara Campal, Madrid (M.H.); University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium (E.V.C.); and Celgene, Summit, NJ (X.W., M.F.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1304369
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1304369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139PMC
October 2013

Current and emerging treatment options in pancreatic cancer.

Clin Adv Hematol Oncol 2013 Aug;11(8):523-5

Medical Director, Clinical Trials Program Virginia G. Piper Cancer Center Scottsdale Health Care Scottsdale, Arizona Clinical Professor of Medicine Translational Genomics Research Institute University of Arizona College of Medicine-Phoenix Phoenix, Arizona.

View Article

Download full-text PDF

Source
August 2013

Determinants of patient screen failures in Phase 1 clinical trials.

Invest New Drugs 2013 Jun 8;31(3):774-9. Epub 2012 Nov 8.

Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, 10510 N 92nd St. Ste 200, Scottsdale, AZ, 85258, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-012-9894-7
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9894-7DOI Listing
June 2013

Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.

Invest New Drugs 2013 Apr 1;31(2):363-9. Epub 2012 May 1.

Sarah Canon Research Institute, 250 25th Avenue, Suite 200, Nashville, TN 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9823-9DOI Listing
April 2013

Clonal evolution and therapeutic resistance in solid tumors.

Front Pharmacol 2013 28;4. Epub 2013 Jan 28.

The Translational Genomics Research Institute Scottsdale, AZ, USA ; Mayo Clinic Arizona Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2013.00002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556559PMC
February 2013

Genomic analysis and selected molecular pathways in rare cancers.

Phys Biol 2012 Dec 29;9(6):065004. Epub 2012 Nov 29.

Norris Comprehensive Cancer Center, Division of Medical Oncology, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1478-3975/9/6/065004DOI Listing
December 2012

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.

Cancer Chemother Pharmacol 2012 Jul 27;70(1):201-5. Epub 2012 Mar 27.

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 W. 10th Street, WD W7123, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-012-1859-1
Publisher Site
http://dx.doi.org/10.1007/s00280-012-1859-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383947PMC
July 2012

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.

Cancer Chemother Pharmacol 2012 Mar 22;69(3):605-12. Epub 2011 Sep 22.

Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Cancer Center, Mail Stop C238, 12850 East Montview Blvd., V20-1223, Aurora, CO, 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1733-6DOI Listing
March 2012

Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case.

Clin Genitourin Cancer 2012 Mar 6;10(1):47-9. Epub 2011 Nov 6.

Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2011.10.002DOI Listing
March 2012

Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

J Clin Pharmacol 2012 Feb;52(2):180-94

University of North Carolina (UNC) Eshelman School of Pharmacy, UNC, Chapel Hill, North CarolinaUNC Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North CarolinaUNC Institute for Pharmacogenomics and Individualized Therapy, UNC, Chapel Hill, North CarolinaCarolina Center for Cancer Nanotechology Excellence, UNC, Chapel Hill, North CarolinaUniversity of Pittsburgh Cancer Institute, Pittsburgh, PennsylvaniaSchool of Medicine, University of Pittsburgh, PittsburghDepartment of Mathematics, Carlow University, PittsburghCKD Research Institute, Chonan, KoreaSeoul National University Hospital, Seoul, Korea.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270010394851
Publisher Site
http://dx.doi.org/10.1177/0091270010394851DOI Listing
February 2012

Allometric scaling of pegylated liposomal anticancer drugs.

J Pharmacokinet Pharmacodyn 2011 Oct 24;38(5):653-69. Epub 2011 Aug 24.

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Suite 1013, CB 7361, Chapel Hill, NC 27599-7361, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-011-9213-5DOI Listing
October 2011

Development of breast cancer in a 21-year-old childhood Wilms' tumor survivor with a BRCA1 2634delC mutation.

Clin Breast Cancer 2011 Aug 3;11(4):268-9. Epub 2011 May 3.

Virginia G. Piper Cancer Center, Scottsdale Healthcare, 10510 N. 92nd Street, Scottsdale, AZ 85258, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2010.11.001DOI Listing
August 2011

Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.

Cancer 2011 Jul 18;117(14):3276-83. Epub 2011 Jan 18.

Translational Genomics Research Institute and Virginia G. Piper Cancer Center, Phoenix/Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25885DOI Listing
July 2011

Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.

J Liposome Res 2011 Jun 14;21(2):158-65. Epub 2010 Jul 14.

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08982104.2010.496085DOI Listing
June 2011

Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.

Ann Surg Oncol 2011 Apr 23;18(4):1122-9. Epub 2010 Nov 23.

Department of Surgery, Stony Brook University Hospital, Stony Brook, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-010-1401-9DOI Listing
April 2011